Latest News and Press Releases
Want to stay updated on the latest news?
-
WHITEHOUSE STATION, N.J. and AMES, Iowa, Nov. 24, 2014 (GLOBE NEWSWIRE) -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NewLink Genetics Corporation (Nasdaq:NLNK),...
-
AUSTIN, Texas, Nov. 17, 2014 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that it will present at the following conferences: At 9:45 am on Tuesday, November 18,...
-
AUSTIN, Texas, Nov. 14, 2014 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that Thomas P. Monath, M.D. has been appointed Chief Scientific and Chief Operations Officer...
-
AMES, Iowa, Nov. 6, 2014 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), today reported consolidated financial results for the third quarter of 2014 and progress in its clinical and...
-
NewLink Genetics to Host Its Third Quarter 2014 Earnings Results Conference Call on November 6, 2014
AMES, Iowa, Oct. 27, 2014 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) will release its third quarter 2014 financial results on Thursday, November 6, 2014. The company has scheduled...
-
AMES, Iowa, Sept. 21, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that it will begin an investigator initiated, randomized, double blind placebo controlled Phase 2 study...
-
AMES, Iowa, Sept. 20, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that Dr. Charles Link, Chairman and CEO, will participate in a panel discussion entitled "Innovation in...
-
AMES, Iowa, Aug. 14, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today...
-
AMES, Iowa, June 19, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that in the second quarter of 2012 it passed the midpoint in enrollment in its Phase 3...
-
AMES, Iowa, June 4, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that data from Phase 1 and Phase 1B studies evaluating NLG8189 (D-1MT, 1-methyl-D-tryptophan or...